K2 Biolabs, Inc. — Form D
K2 Biolabs, Inc. of Houston, TX, a company, filed a Form D exempt-offering notice with the SEC on 2023-08-02. The offering totals $3.0M, of which $616K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-08-02
- Form: D
- Accession: 0001567619-23-006723
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $3.0M
- Amount sold: $616K
- Remaining: $2.4M
- Investors: 7
- Date of first sale: 2023-06-05
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-488578
Issuer
- Name: K2 Biolabs, Inc.
- CIK: 0001848448
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 2710 Reed Road , Ste. 160, Houston, TX, 77051
- Phone: (347) 752-3124
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Andrew DeSomma | Director | Houston, TX |
| Gerard Fleury | Director | Houston, TX |
| Kieron Jones | Director | Houston, TX |
| Kevin Slawin | Director | Houston, TX |
| Clifford J Stocks | Director | HOUSTON, TX |
| Andrew J Strong | Director | Houston, TX |
| Daniel J Clark | Executive Officer | Houston, TX |
| Kieron Jones | Executive Officer | Houston, TX |
| Clifford Stocks | Director | Houston, TX |
| Andrew Strong | Director | HOUSTON, TX |
Other filings by this issuer (1)
More